Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 4;105(5):837-854.e9.
doi: 10.1016/j.neuron.2019.12.007. Epub 2020 Jan 2.

TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge

Affiliations
Free article

TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge

Alicia A Nugent et al. Neuron. .
Free article

Abstract

Loss-of-function (LOF) variants of TREM2, an immune receptor expressed in microglia, increase Alzheimer's disease risk. TREM2 senses lipids and mediates myelin phagocytosis, but its role in microglial lipid metabolism is unknown. Combining chronic demyelination paradigms and cell sorting with RNA sequencing and lipidomics, we find that wild-type microglia acquire a disease-associated transcriptional state, while TREM2-deficient microglia remain largely homeostatic, leading to neuronal damage. TREM2-deficient microglia phagocytose myelin debris but fail to clear myelin cholesterol, resulting in cholesteryl ester (CE) accumulation. CE increase is also observed in APOE-deficient glial cells, reflecting impaired brain cholesterol transport. This finding replicates in myelin-treated TREM2-deficient murine macrophages and human iPSC-derived microglia, where it is rescued by an ACAT1 inhibitor and LXR agonist. Our studies identify TREM2 as a key transcriptional regulator of cholesterol transport and metabolism under conditions of chronic myelin phagocytic activity, as TREM2 LOF causes pathogenic lipid accumulation in microglia.

Keywords: APOE; Alzheimer’s disease; TREM2; cholesterol; cholesteryl ester; lipid metabolism; microglia; myelin; neurodegeneration; phagocytosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests All authors are paid employees and shareholders of Denali Therapeutics. R.J.W. is a founder and member of the Board of Directors of Denali. Denali has filed patent applications related to the subject matter of this paper.

Comment in

Publication types

MeSH terms